Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Asymmetric van der Waals forces drive orientation of compositionally anisotropic nanocylinders within smectic arrays: experiment and simulation.

Smith BD, Fichthorn KA, Kirby DJ, Quimby LM, Triplett DA, González P, Hernández D, Keating CD.

ACS Nano. 2014 Jan 28;8(1):657-70. doi: 10.1021/nn405312x. Epub 2013 Dec 11.

2.

Inhibition of Binding of β2-Glycoprotein 1 to Phosphatidylserine by Polymyxin B, a Lupus-Like Anticoagulant.

Uchman B, Triplett DA.

Clin Appl Thromb Hemost. 2015 Sep;21(6):584-5. doi: 10.1177/1076029613512417. Epub 2013 Nov 24.

PMID:
24275099
3.

Entropic forces and directed alignment of hard squares in suspensions of rods and disks.

Triplett DA, Fichthorn KA.

J Chem Phys. 2010 Oct 14;133(14):144910. doi: 10.1063/1.3503975.

PMID:
20950044
4.

Assembly of gold nanowires by sedimentation from suspension: Experiments and simulation.

Triplett DA, Quimby LM, Smith BD, Rodríguez DH, St Angelo SK, González P, Keating CD, Fichthorn KA.

J Phys Chem C Nanomater Interfaces. 2010 Apr 29;114(16):7346-7355.

5.

Monte Carlo simulation of two-dimensional hard rectangles: confinement effects.

Triplett DA, Fichthorn KA.

Phys Rev E Stat Nonlin Soft Matter Phys. 2008 Jan;77(1 Pt 1):011707. Epub 2008 Jan 31.

PMID:
18351866
6.

Thrombophilias and recurrent pregnancy loss.

Kutteh WH, Triplett DA.

Semin Reprod Med. 2006 Feb;24(1):54-66. Review.

PMID:
16418978
7.

Antiphospholipid antibodies.

Triplett DA.

Clin Adv Hematol Oncol. 2003 Dec;1(12):726-30. Review.

PMID:
16258476
8.

Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients.

Asherson RA, Espinosa G, Cervera R, Gómez-Puerta JA, Musuruana J, Bucciarelli S, Ramos-Casals M, Martínez-González AL, Ingelmo M, Reverter JC, Font J, Triplett DA.

Ann Rheum Dis. 2005 Jun;64(6):943-6.

9.

Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.

Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, Murphy A, Lu Y, Costigan TM, Rhine C, Levin B, Triplett DA, Mohr JP; APASS Investigators.

JAMA. 2004 Feb 4;291(5):576-84.

PMID:
14762036
10.
11.

The catastrophic antiphospholipid syndrome--Asherson's syndrome.

Piette JC, Cervera R, Levy RA, Nasonov EL, Triplett DA, Shoenfeld Y.

Ann Med Interne (Paris). 2003 Sep;154(4):195-6. No abstract available.

PMID:
14593307
12.

Lupus anticoagulants: diagnosis and management.

Triplett DA.

Curr Hematol Rep. 2003 Jul;2(4):271-2. Review. No abstract available.

PMID:
12901323
13.

Antiphospholipid antibodies.

Triplett DA.

Arch Pathol Lab Med. 2002 Nov;126(11):1424-9. Review.

PMID:
12421152
14.

Gamma371 Thr-->Ile substitution in the fibrinogen gammaD domain causes hypofibrinogenaemia.

Brennan SO, Wyatt JM, Fellowes AP, Dlott JS, Triplett DA, George PM.

Biochim Biophys Acta. 2001 Dec 17;1550(2):183-8.

PMID:
11755207
15.

The evaluation of clotting times in the laboratory detection of lupus anticoagulants.

Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wisløff F.

Thromb Res. 2001 Nov 15;104(4):275-82.

PMID:
11728529
16.

Oxidized low-density lipoprotein and autoimmune antibodies in patients with antiphospholipid syndrome with a history of thrombosis.

Zhao D, Ogawa H, Wang X, Cameron GS, Baty DE, Dlott JS, Triplett DA.

Am J Clin Pathol. 2001 Nov;116(5):760-7.

PMID:
11710695
17.

Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I.

McNeeley PA, Dlott JS, Furie RA, Jack RM, Ortel TL, Triplett DA, Victoria EJ, Linnik MD.

Thromb Haemost. 2001 Aug;86(2):590-5.

PMID:
11522008
18.

When to suspect hypercoagulability and how to investigate it.

Marques MB, Triplett DA.

Ann Diagn Pathol. 2001 Jun;5(3):177-83. Review.

PMID:
11436173
19.

Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests.

Galli M, Dlott J, Norbis F, Ruggeri L, Cler L, Triplett DA, Barbui T.

Thromb Haemost. 2000 Dec;84(6):1012-6.

PMID:
11154107
20.

Elevated anti-annexin V antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities.

Ogawa H, Zhao D, Dlott JS, Cameron GS, Yamazaki M, Hata T, Triplett DA.

Am J Clin Pathol. 2000 Oct;114(4):619-28.

PMID:
11026109
21.

Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS).

Triplett DA, Asherson RA.

Am J Hematol. 2000 Oct;65(2):154-9. Review.

PMID:
10996834
22.

Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls.

Triplett DA.

J Autoimmun. 2000 Sep;15(2):173-8. Review.

PMID:
10968905
23.

Coagulation and bleeding disorders: review and update.

Triplett DA.

Clin Chem. 2000 Aug;46(8 Pt 2):1260-9. Review.

24.

Proteolytic cleavage of beta(2)-glycoprotein I: reduction of antigenicity and the structural relationship.

Matsuura E, Inagaki J, Kasahara H, Yamamoto D, Atsumi T, Kobayashi K, Kaihara K, Zhao D, Ichikawa K, Tsutsumi A, Yasuda T, Triplett DA, Koike T.

Int Immunol. 2000 Aug;12(8):1183-92.

PMID:
10917893
26.

Prednisolone inhibits endotoxin-induced disseminated intravascular coagulation and improves mortality in rats: importance of inflammatory cytokine suppression.

Yamazaki M, Aoshima K, Mizutani T, Ontachi Y, Saito M, Morishita E, Asakura H, Matsuda T, Triplett DA.

Blood Coagul Fibrinolysis. 1999 Sep;10(6):321-30.

PMID:
10493213
27.

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA.

Arthritis Rheum. 1999 Jul;42(7):1309-11. Review. No abstract available.

28.

Diagnosing antiphospholipid antibody syndrome.

Dlott JS, Triplett DA.

CAP Today. 1999 Mar;13(3):84-8. No abstract available.

PMID:
10350909
29.

A method for proficiency testing of small peer groups in the College of American Pathologists Coagulation Surveys.

Cunningham MT, Praestgaard J, Styer PE, Brandt JT, Fairweather RB, Laposata M, Olson JD, Sosolik RC, Triplett DA.

Arch Pathol Lab Med. 1999 Mar;123(3):199-205.

PMID:
10086507
30.

Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies.

Ieko M, Ichikawa K, Triplett DA, Matsuura E, Atsumi T, Sawada K, Koike T.

Arthritis Rheum. 1999 Jan;42(1):167-74.

31.

Many faces of lupus anticoagulants.

Triplett DA.

Lupus. 1998;7 Suppl 2:S18-22. Review.

PMID:
9814666
32.

College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy.

Fairweather RB, Ansell J, van den Besselaar AM, Brandt JT, Bussey HI, Poller L, Triplett DA, White RH.

Arch Pathol Lab Med. 1998 Sep;122(9):768-81. Review.

PMID:
9740135
33.

Prothrombin fragment 1 + 2 measures treatment effect in patients with antiphospholipid syndrome.

Yamazaki M, Asakura H, Saito M, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Aoshima K, Matsuda T, Triplett DA.

Thromb Res. 1998 Aug 1;91(3):121-8.

PMID:
9733155
34.

Antiphospholipid-protein antibodies and ischemic stroke: not just cardiolipin any more.

Tanne D, Triplett DA, Levine SR.

Stroke. 1998 Sep;29(9):1755-8. No abstract available.

PMID:
9731590
35.

Current recommendations for warfarin therapy. Use and monitoring.

Triplett DA.

Med Clin North Am. 1998 May;82(3):601-11. Review.

PMID:
9646782
36.

The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article.

Peterson P, Hayes TE, Arkin CF, Bovill EG, Fairweather RB, Rock WA Jr, Triplett DA, Brandt JT.

Arch Surg. 1998 Feb;133(2):134-9.

PMID:
9484723
37.

Simultaneous occurrence of lupus anticoagulant and factor VIII inhibitors.

Triplett DA.

Am J Hematol. 1997 Nov;56(3):195-6. No abstract available.

38.

Lupus anticoagulants: diagnostic dilemma and clinical challenge.

Triplett DA.

Clin Lab Sci. 1997 Jul-Aug;10(4):223-8. Review.

PMID:
10169622
39.

[A study on antiprothrombin antibodies in antiphospholipid syndrome].

Ieko M, Triplett DA, Kohno M, Ohmoto A, Notoya A, Sawada K, Koike T.

Rinsho Ketsueki. 1997 May;38(5):426-32. Japanese.

PMID:
9194388
40.
41.
42.

Frequent difficulties encountered in the laboratory diagnosis of antiphospholipid-protein antibodies.

Triplett DA.

Ann Med Interne (Paris). 1996 Sep;147 Suppl 1:5-9. Review.

PMID:
8952751
43.

APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method.

Hoagland LE, Triplett DA, Peng F, Barna L.

Thromb Res. 1996 Sep 1;83(5):363-73.

PMID:
8873345
44.

Evaluation of the minimally prolonged APTT: Passovoy factor or lupus anticoagulant?

Triplett DA.

J Pediatr Hematol Oncol. 1996 Aug;18(3):247-8. No abstract available.

PMID:
8689334
45.

Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system.

Igarashi M, Matsuura E, Igarashi Y, Nagae H, Ichikawa K, Triplett DA, Koike T.

Blood. 1996 Apr 15;87(8):3262-70.

48.

Protean clinical presentation of antiphospholipid-protein antibodies (APA).

Triplett DA.

Thromb Haemost. 1995 Jul;74(1):329-37. Review.

PMID:
8578480
49.

Antiphospholipid-protein antibodies: laboratory detection and clinical relevance.

Triplett DA.

Thromb Res. 1995 Apr 1;78(1):1-31. Review. No abstract available.

PMID:
7778063

Supplemental Content

Loading ...
Support Center